Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial reported median PFS of 8.3 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback